---
schema_version: "secwatch.filing_event.v1"
accession: "0001534969-22-000129"
form_type: "8-K"
ticker: "SERA"
cik: "0001534969"
company_name: "SERA PROGNOSTICS, INC."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:11:52.586262+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed

## Summary
- Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.
- Operating expenses $11.3M, up from $9.5M; R&D $4.2M, SG&A $7.0M.
- Cash, equivalents & securities $111.2M at Sept 30, 2022.
- Banner Health signed for PreTRM test under Medicaid plan (~300k members); revenue possible Q4 2022.
- PRIME study on track; interim look expected 2023; preeclampsia validation data by year-end 2022.

## SEC filing metadata
- accession: 0001534969-22-000129
- form_type: 8-K
- ticker: SERA
- cik: 0001534969
- company_name: SERA PROGNOSTICS, INC.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/0001534969-22-000129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/sera-20221109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534969-22-000129
- JSON: https://secwatch.observer/filing/0001534969-22-000129.json
- Plain text: https://secwatch.observer/filing/0001534969-22-000129.txt

## Key facts
- Earnings Releases
  SERA PROGNOSTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $87,000, net income $10.7 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $87,000
  - Net income: $10.7 million
  - Result: reported results
  source text: traction that we believe will create a more significant impact on our top-line results in 2023 and beyond.” Third Quarter 2022 Financial Results Third quarter 2022 revenue of $87,000 compared to $23,000 for the same period of 2021. Total operating expenses were $11.3 million, up from $9.5 million for the third quarter of 2021. Research and development expenses
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534969/000153496922000129/0001534969-22-000129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.